Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm

NCT05039359 is registered in ClinicalTrials.gov with InCarda Therapeutics, Inc. as lead sponsor.

NCT NCT05039359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm
Lead sponsor
InCarda Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
April 26, 2022
Completion date
May 22, 2023
Enrollment
54 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal atrial fibrillation